Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Health-economic Evaluation of the IPS (Individual Placement and Support) Model for Helping People With Severe Mental Disorders Access Employment in the Ordinary Labor Market, Compared to Standard Methods of Helping People Return to Work: a Prospective Real-life Study

NCT07206316 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-10-02
Last updated
2025-10-03

Condition(s) studied

Severe Mental Disorders

Investigational drug(s) / intervention(s)

Individual Placement and Support ModelStandard Method

Individual Placement and Support Model: The Individual Placement and Support (IPS) model is an employment support program specifically designed for people with severe mental illness (Bond, Drake, \& Becker, 2012). The core philosophy of IPS is that anyone can obtain competitive employment in the open labor market, provided it is the right job combined with appropriate support. IPS support is delivered by a job coach, specifically trained in this model, who devotes their entire working time to assisting patients in their vocational integration.

Standard Method: In psychiatric wards, patients who wish to do so are usually offered support to initiate the process of returning to competitive employment in the open labor market. This assistance is provided by the social workers (such as social workers or educators) within the care unit.

Study summary

The Individual Placement and Support (IPS) model was developed in the United States in the 1990s to help people with severe mental health issues get back into regular jobs. This model is based on the idea that a quick job search that takes into account what patients want, followed by ongoing and intensive support in the community, is especially good for this group. To date, although the effectiveness of the IPS model has been widely demonstrated (for a review, see Metcalfe et al., 2018), only a few studies have evaluated its efficiency in foreign contexts (Knapp et al., 2013; Christensen et al., 2020).

Although the IPS model has been in place in France for around ten years, no studies have yet been conducted to validate its efficiency in the French healthcare system.

The main objective of this prospective, real-life, multicenter study is to evaluate the efficiency of the IPS practice model compared to the conventional method of follow-up by social workers for patients with severe mental illness in terms of cost per additional day worked, from a collective perspective.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥ 18 years * Participant with a chronic psychiatric disorder causing significant functional impairment * Unemployed * Wishing to return to competitive employment in the open labor market * Informed about the study and consenting to participate * Able to read french Exclusion Criteria: * Individuals not eligible for legal employment due to irregular residency status in France * Individuals not affiliated with a social security system * Individuals wishing to work in a sheltered/protected setting * Individuals currently enrolled in a training program * Individuals refusing to participate in the study

Primary outcome measure(s)

  • Efficiency of the IPS practice model compared to the conventional method of follow-up by social workers for patients with severe mental illness — 18 months
    Incremental cost-effectiveness ratio (ICER) expressed as cost per additional day worked at 18 months, from a collective perspective, of the IPS practice model in patients with severe mental disorders.

Trial sites (11)

FacilityCityRegionStatus
CH Cesame Angers France
CH George Sand Bourges France
Centre hospitalier Le Vinatier Bron France
CHI EPSM Oise Clermont France
University hospital Clermont-Ferrand France
Centre Hospitalier Marius Lacroix La Rochelle France
CH Esquirol Limoges France
Hôpital la Colombière Montpellier France
PRISM 45 Orléans France
CH Le Rouvray Rouen France
University hospital Tours France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07206316 on ClinicalTrials.gov ↗ ← All trials in France